Holen Sie sich die Stockscreener-App
2.69
0.74%
-0.02
Schlusskurs vom Vortag:
$2.71
Offen:
$2.72
24-Stunden-Volumen:
1.10M
Relative Volume:
0.47
Marktkapitalisierung:
$241.89M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.934
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
-2.54%
1M Leistung:
+17.47%
6M Leistung:
+78.15%
1J Leistung:
-28.27%
1-Tages-Spanne:
$2.6501
$2.74
1-Wochen-Bereich:
$2.555
$2.84
52-Wochen-Spanne:
$0.9101
$4.12
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.69 | 230.20M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Ieq Capital LLC Increases Stake in Editas Medicine, Inc. $EDIT - MarketBeat
Nuveen LLC Makes New Investment in Editas Medicine, Inc. $EDIT - MarketBeat
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? - sharewise.com
Editas Medicine Q3 EPS Estimate Increased by Zacks Research - MarketBeat
Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 26% - 富途牛牛
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry - simplywall.st
Wells Fargo & Company Issues Positive Forecast for Editas Medicine (NASDAQ:EDIT) Stock Price - MarketBeat
Editas Medicine price target raised to $4 from $3 at Wells Fargo - MSN
Is Editas Medicine Inc. a good stock for dollar cost averagingJuly 2025 Momentum & AI Driven Stock Price Forecasts - 뉴스영
Editas Medicine Bets On Next-Gen Gene Editing - Finimize
Statistical indicators supporting Editas Medicine Inc.’s strengthRate Hike & AI Driven Stock Reports - Newser
Using portfolio simulators with Editas Medicine Inc. includedJuly 2025 Sector Moves & Growth Focused Entry Reports - Newser
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novan (NOVN) and Editas Medicine (EDIT) - The Globe and Mail
What drives Editas Medicine Inc.’s stock price2025 Top Gainers & Capital Efficient Trading Techniques - خودرو بانک
What are Editas Medicine Inc.’s technical support levelsJuly 2025 Outlook & High Return Stock Watch Alerts - خودرو بانک
Can Editas Medicine Inc. weather a recession2025 Year in Review & Verified Technical Signals - خودرو بانک
Is Editas Medicine Inc. a momentum stockJuly 2025 Recap & Accurate Intraday Trade Tips - خودرو بانک
Can Editas Medicine Inc. expand into new marketsWeekly Stock Report & Weekly Consistent Profit Watchlists - خودرو بانک
Predicting Editas Medicine Inc. trend using moving averages2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - Newser
Volatility Watch: Is Editas Medicine Inc. stock influenced by commodity prices2025 Technical Patterns & Detailed Earnings Play Strategies - خودرو بانک
Is Editas Medicine Inc. forming a bottoming baseQuarterly Profit Summary & Safe Capital Growth Stock Tips - Newser
Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating - AInvest
Using Ichimoku Cloud for Editas Medicine Inc. technicalsWeekly Investment Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is Editas Medicine Inc. stock ready for a breakoutJuly 2025 Big Picture & Smart Investment Allocation Tips - Newser
Real time scanner hits for Editas Medicine Inc. explainedMarket Weekly Review & Low Drawdown Trading Techniques - Newser
Editas Medicine at Cantor Global: CRISPR Shift and Financial Resilience By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Stock Price Crosses Below Fifty Day Moving AverageTime to Sell? - MarketBeat
How to escape a deep drawdown in Editas Medicine Inc.2025 Stock Rankings & Free Verified High Yield Trade Plans - Newser
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $5.10 Consensus Target Price from Analysts - MarketBeat
Editas Medicine at Cantor Global: CRISPR Shift and Financial Resilience - Investing.com
Can volume confirm reversal in Editas Medicine Inc.Quarterly Earnings Report & Free Fast Gain Swing Trade Alerts - Newser
Using data models to predict Editas Medicine Inc. stock movementPortfolio Return Report & Low Risk High Reward Trade Ideas - Newser
Is Editas Medicine Inc. stock entering bullish territoryPortfolio Risk Report & Reliable Price Action Trade Plans - Newser
How to build a custom watchlist for Editas Medicine Inc.Recession Risk & AI Forecast Swing Trade Picks - Newser
Is Editas Medicine Inc. showing signs of accumulation2025 Year in Review & Low Risk High Reward Trade Ideas - Newser
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol - Zacks Investment Research
Evaluating Editas Medicine Inc. with trendline analysisQuarterly Profit Summary & Consistent Growth Stock Picks - Newser
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $4 to $4 - 富途牛牛
Editas Medicine at Wells Fargo Conference: Gene Editing Milestone - Investing.com
Activity Recap: How does Editas Medicine Inc. score in quality rankingsDay Trade & Free Accurate Trade Setup Notifications - خودرو بانک
what the charts say about editas medicine inc. todayQuarterly Profit Summary & Smart Allocation Stock Reports - Newser
Is now the right time to enter Editas Medicine Inc.Dividend Hike & Low Drawdown Investment Ideas - خودرو بانک
How to track smart money flows in Editas Medicine Inc.Weekly Trade Review & Verified Technical Signals - Newser
Is it time to cut losses on Editas Medicine Inc.2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Is Editas Medicine Inc. forming a reversal patternTrade Volume Summary & Weekly Stock Breakout Alerts - Newser
What machine learning models say about Editas Medicine Inc.Weekly Stock Report & High Accuracy Swing Trade Signals - Newser
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):